We work with our partners to identify, design and execute joint research activities more efficiently and more strategically so that milestones are met as quickly and efficiently as possible.
These techniques include extensive experience in bronchoscopy of subjects post-drug delivery and direct (filter paper) and directed lavage techniques for making pharmacokinetic measurements of lung/airway deposition. Also, exhaled breath condensate (EBC) can be analyzed with high sensitivity by mass spectroscopy offering the ability to measure the drug and metabolite concentration in airway surface liquid.
UNC has developed the capacity to measure the respiratory microbiome with 16S-454 pyrosequencing and Illumina MiSeq technologies. This technique has already been applied to studies of acute exacerbations in CF and COPD and measurement of antibiotic effects.
Center for Environmental Medicine, Asthma & Lung Biology
The CEMALB has great emphasis on translational studies of lung disease and biology.
–Systemic effects of inhaled agents (primarily CV)
Significant Clinical Research Infrastructure:
•In vitro primary epithelial cell models
•Clinical Research (study coordination, scintigraphy, exercise challenge, bronchoscopy)
–PM (CAPS, Woodsmoke)
–Other gases (NO2)
–IND for allergen and LPS challenge, approvals for ozone
CEMALB and EPA investigators have developed phase I and IIa programs focused on potential interventions to mitigate the effect of pollutants on airway inflammation
Studies of genetic and epigenetic regulators of pollutant response, and chemoprevention and pharmacologic intervention are established.
Environmental Challenge Studies and Exposure
The Center for Environmental Medicine has exposure chambers that allow for both short-term and long term human exposure studies.
Approved challenge studies include:
•House Dust Mite
CEMALB: Sputum Slide Reading, Biomarker and Biospecimen Core
The Core is a major resource for sample acquisition, processing, allocation, analysis, storage, tracking and security. The core serves as a central reading lab for sputum slides.
Biomarker Analysis in sputum/BAL/nasal lavage
•Total and Differential Leukocytes Counts
•Proteomics on fluid phase components
•Flow cytometric markers of cell function (phagocytosis, intracellular oxidative burst, cell surface marker expression)
•Genomics: gene array; genotyping
•% solids content
•Ex vivo stimulation assays
•Single cell isolation and mRNA analysis using Isoraft technology
•Banked human samples that include sputum supernatants, sputum cell pellets in Trizol, nasal lavage, EBC, serum, blood cell pellets in Trizol
•Biorepository samples from the following subject cohorts at baseline, pre and post inhalation challenge (LPS, Ozone, virus, allergen, methacholine, hypertonic saline)
•Healthy controls – Asthmatics – Allergics/atopics – Smokers – COPD – CF – eCig users, Hookah users
•Sputum endpoints on healthy and diseased subjects
•Sputum producing capability (producers vs non-producers)
•Responder vs non-responder status to inhalation challenges (ozone, lps)
•Genotype status for target polymorphisms (GSTM1null)
Mucociliary Clearance & Aerosol Research
The mission of the Mucociliary Clearance and Aerosol Research Laboratory is to use inhaled aerosols as a tool for studying lung physiology and; to improve treatment of pulmonary diseases such as cystic fibrosis, asthma, and chronic obstructive lung disease.
Areas of Focus
Our extensive knowledge and experience in the use of radiolabeled aerosols and gamma scintigraphy allows us to assess clearance of mucus from the airways and the delivery of aerosols to the lung. We provide state-of-the-art clinical, animal, and bench research services for evaluating:
•The effectiveness of new therapies for improving clearance of secretions from the lung and;
•The efficiency of drug delivery to the lungs for new aerosol treatment devices.
Pulmonary and Critical Care Clinical Research Facility
The Division of Pulmonary Medicine at UNC cares for patients with a wide range of pulmonary diseases, specializing in the care of lung cancer, sleep disorders, cystic fibrosis, pulmonary hypertension, non-CF bronchiolitis, lung transplant, a1-antitrypsin deficiency, sarcoidosis, pleural diseases and primary ciliary dyskinesia.
•~4000 square feet of laboratory space, 4 patient exam rooms and waiting room space dedicated to clinical research
•Mucociliary Clearance Imaging Lab
•Specimen Processing/storage facility
•Fully equipped Pulmonary Function Labs for spirometry (including multiple portable KoKo spirometers), lung volumes, diffusion capacity, multiple breath washouts, nasal potential difference, sputum induction, ECG and vital signs
UNC Biomedical Research Imaging Center
The BRIC contains world-class imaging equipment, including a hybrid MRI/PET whole body scanner, a 7 Tesla MRI whole body scanner, and a cyclotron – and is one of only two academic medical institutions in the United States that houses all three pieces of technology at one site.
•Radiochemistry: Contains all equipment needed to support radiopharmaceutical development and production for molecular imaging studies under GMP.
•PET probes include [18F]FDG, [11C]FMAU, [18F]FMAU, [18F]FHBG, [18F]5-fluorouracil, [15O]H2O, [15O]CO, [15O]CO2, [13N]NH3, and [18F-FB/64Cu-DOTA]-RGD et al.
•GE PETtrace 880 Cyclotron is capable of accelerating both protons and deuterons for maximum flexibility.
•ABT Biomarker Generator is dedicated to the production of 18F-FDG for clinical studies
•Small Animal Imaging includes: 9.4T MRI, Optical Systems, PET/CT, SPECT, Ultrasound and CT Systems.
•Human Imaging: 3T MRI, PET/MR, PET/CT or 7T MRI equipment is available.
•Hyperpolarized 19 F Lung Imaging